MPT-0118 is under clinical development by Monopteros Therapeutics and currently in Phase II for Chordoma. According to GlobalData, Phase II drugs for Chordoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MPT-0118 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MPT-0118 overview

MPT-0118 is under development for the treatment of advanced or metastatic refractory solid tumors, chordoma, gastric cancer, breast cancer. It is administered through oral route and acts by targeting mucosa associated lymphoid tissue lymphoma translocation protein 1 (MALT1).

Monopteros Therapeutics overview

Monopteros Therapeutics is a biotechnology company that is engaged in the research and development of inhibitor cells. It conducts clinical trials on reprogramming regulatory T cells in solid tumors. The company is headquartered in Rockport, Massachusetts, the US.

For a complete picture of MPT-0118’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.